b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="eid" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2725890/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza </title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725890/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Emerging Infectious Diseases" /><meta name="citation_title" content="Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza " /><meta name="citation_authors" content="Vernon J. Lee, Mark I. Chen" /><meta name="citation_date" content="March 2007" /><meta name="citation_issue" content="3" /><meta name="citation_volume" content="13" /><meta name="citation_firstpage" content="449" /><meta name="citation_doi" content="10.3201/eid1303.060309" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2725890/?report=abstract" /><meta name="citation_pmid" content="17552099" /><meta name="DC.Title" content="Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza " /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Centers for Disease Control and Prevention" /><meta name="DC.Contributor" content="Vernon J. Lee" /><meta name="DC.Contributor" content="Mark I. Chen" /><meta name="DC.Date" content="2007 Mar" /><meta name="DC.Identifier" content="10.3201/eid1303.060309" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza " /><meta property="og:type" content="article" /><meta property="og:description" content="We used a deterministic SEIR (susceptible-exposed-infectious-removed) meta-population model, together with scenario, sensitivity, and simulation analyses, to determine stockpiling strategies for neuraminidase inhibitors that would minimize absenteeism ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725890/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-eid.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2725890/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2725890/pdf/06-0309.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1BC4A7E9A3BD110000000004460446.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/782/">Emerg Infect Dis</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/180925/">v.13(3); 2007 Mar</a></li><li class="accid">PMC2725890</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-eid.gif" alt="Logo of eid" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,500,75" alt="Emerging Infectious Diseases" title="Emerging Infectious Diseases" href="http://wwwnc.cdc.gov/eid/" ref="reftype=publisher&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Emerg Infect Dis</span>. 2007 Mar; 13(3): 449\xe2\x80\x93457. </span></div><div>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.3201%2Feid1303.060309" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.3201/eid1303.060309</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2725890</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/17552099">17552099</a></div></div></div></div><h1 class="content-title">Effectiveness of Neuraminidase Inhibitors for Preventing Staff Absenteeism during Pandemic Influenza </h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Lee%20VJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17552099" class="affpopup" co-rid="_co_idm140657680090832" co-class="co-affbox">Vernon J. Lee</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>*</sup> and  <a href="/pubmed/?term=Chen%20MI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17552099" class="affpopup" co-rid="_co_idm140657676744464" co-class="co-affbox">Mark I. Chen</a><sup>*</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140657680090832"><h3 class="no_margin">Vernon J. Lee</h3><p><sup>*</sup>Tan Tock Seng Hospital, Singapore</p><div>Find articles by <a href="/pubmed/?term=Lee%20VJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17552099">Vernon J. Lee</a></div></div><div id="_co_idm140657676744464"><h3 class="no_margin">Mark I. Chen</h3><p><sup>*</sup>Tan Tock Seng Hospital, Singapore</p><div>Find articles by <a href="/pubmed/?term=Chen%20MI%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=17552099">Mark I. Chen</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140657679045520_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140657679045520_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140657679045520_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1"><sup>*</sup>Tan Tock Seng Hospital, Singapore</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div><div id="cor1">Address for correspondence: Vernon J Lee, Block 802, Communicable Disease Centre, Moulmein Rd, Singapore 308433; email: <a href="mailto:dev@null" data-email="moc.liamtoh@mjlnonrev" class="oemail">moc.liamtoh@mjlnonrev</a></div></div><div class="fm-article-notes fm-panel half_rhythm"></div><div class="permissions fm-panel half_rhythm hide" id="idm140657679045520_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright notice</a> </div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2725890/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2>Associated Data</h2><dl data-count="2" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">Appendix Modified SEIR Model</div><div><a href="/pmc/articles/PMC2725890/bin/06-0309_app-s1.pdf" data-ga-action="click_feat_suppl">06-0309_app-s1.pdf</a><span style="color:gray"> (65K)</span></div><div class="small guid">GUID:\xc2\xa0DB9A9024-667D-494E-BBD7-A35B84BBAA1D</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin">Technical Appendix Supplementary material including additional methodology, results, and discussion.</div><div><a href="/pmc/articles/PMC2725890/bin/06-0309_Techapp-s2.pdf" data-ga-action="click_feat_suppl">06-0309_Techapp-s2.pdf</a><span style="color:gray"> (283K)</span></div><div class="small guid">GUID:\xc2\xa066B5FE3C-DDDD-458A-9D13-01AE55CC652A</div></div></dd></dl></div><div id="idm140657679939648" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140657679939648title">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">We used a deterministic SEIR (susceptible-exposed-infectious-removed) meta-population model, together with scenario, sensitivity, and simulation analyses, to determine stockpiling strategies for neuraminidase inhibitors that would minimize absenteeism among healthcare workers. A pandemic with a basic reproductive number (R<sub>0</sub>) of 2.5 resulted in peak absenteeism of 10%. Treatment decreased peak absenteeism to 8%, while 8 weeks&#x02019; prophylaxis reduced it to 2%. For pandemics with higher R<sub>0</sub>, peak absenteeism exceeded 20% occasionally and 6 weeks&#x02019; prophylaxis reduced peak absenteeism by 75%. Insufficient duration of prophylaxis increased peak absenteeism compared with treatment only. Earlier pandemic detection and initiation of prophylaxis may render shorter prophylaxis durations ineffective. Eight weeks&#x02019; prophylaxis substantially reduced peak absenteeism under a broad range of assumptions for severe pandemics (peak absenteeism &#x0003e;10%). Small investments in treatment and prophylaxis, if adequate and timely, can reduce absenteeism among essential staff.</p></div><div class="sec"><strong class="kwd-title">Keywords:  </strong><span class="kwd-text">influenza, modeling, absenteeism, healthcare worker, treatment, prophylaxis, policy, pandemic, research</span></div></div><div id="idm140657673674832" class="tsec sec headless whole_rhythm"><p id="__p3" class="p p-first">Concerns regarding the advent and impact of the next influenza pandemic have led &#x0003e;120 countries to develop pandemic preparedness plans (<a href="#R1" rid="R1" class=" bibr popnode"><em>1</em></a>). Studies have shown that treatment with neuraminidase inhibitors and prophylaxis of selected subpopulations are cost-effective strategies to limit the pandemic&#x02019;s impact on the healthcare system (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154072"><em>2</em></a>,<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154071"><em>3</em></a>). However, supplies of neuraminidase inhibitors are limited, and countries may not have the financial resources to purchase large stockpiles. Policymakers will thus have to determine priorities for treatment and prophylaxis.</p><p id="__p4">One priority is to maintain essential services during the pandemic&#x02019;s peak&#x02014;to ensure business continuity and mitigate the resultant damage. Absenteeism of essential staff from work should be minimized to prevent service disruption when most needed. This is particularly crucial for healthcare workers (HCWs) because they may have an increased risk for exposure and illness while facing a surge in demand for healthcare services.</p><p id="__p5" class="p">A recent study proposed that hospitals should consider stockpiling neuraminidase inhibitors for treatment and prophylaxis (<a href="#R4" rid="R4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979800"><em>4</em></a>). To provide policy guidance to reduce the pandemic&#x02019;s impact on HCWs, this study analyzed the use of neuraminidase inhibitors in minimizing absenteeism by simulating an HCW population in a transmission dynamics model.</p></div><div id="__sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec1title">Methods</h2><div id="__sec2" class="sec sec-first"><h3 id="__sec2title">Model Structure and Dynamics</h3><p id="__p6" class="p p-first">We used a deterministic, modified SEIR (susceptible-exposed-infectious-removed) meta-population model to evaluate strategies for minimizing absenteeism among HCWs during an influenza pandemic. The model consisted of 2 distinct populations in Singapore: the general population and an HCW population (<a href="/pmc/articles/PMC2725890/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>). Singapore&#x02019;s mid-year population in 2005 was 4.35 million, and the public HCW population of 20,000 represented essential staff that required protection. Oseltamivir was the neuraminidase-inhibitor modeled because of its effectiveness in treatment and prophylaxis, good safety profile, and common use in national stockpiles (<a href="#R5" rid="R5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979808"><em>5</em></a>&#x02013;<a href="#R8" rid="R8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979813"><em>8</em></a>). Standard treatment regimen was 75 mg, twice per day for 5 days, and prophylaxis required 75 mg once per day for as long as planned.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a href="/pmc/articles/PMC2725890/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657681321968" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2725890_06-0309-F1.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-F1.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2725890/bin/06-0309-F1.jpg" /></a></div><div id="largeobj_idm140657681321968" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/figure/F1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="/pmc/articles/PMC2725890/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p7">A) Modified SEIR (susceptible-exposed-infectious-removed) model for transmission of pandemic influenza within the general population and healthcare worker (HCW) subpopulation. B) Absenteeism among exposed HCWs.</p></div></div></div><p id="__p8">This study assumed that the general population did not receive treatment or prophylaxis with oseltamivir. Three strategies for HCWs were considered: no action (providing symptomatic relief), treatment only (early treatment of all symptomatic HCW infections), and prophylaxis (prophylaxis together with early treatment). Different predetermined prophylaxis substrategies were considered, based on the weeks of prophylaxis; each additional week required 140,000 doses in addition to separate treatment stockpiles. To be conservative, we assumed that prophylaxis stockpiles would last only for the planned duration. Separate analyses explored the effect of stopping prophylaxis after individual clinical infection, with redistribution of prophylaxis doses to other HCWs to prolong prophylaxis beyond the planned duration; however, this strategy is only possible if tests can promptly confirm individual infection and logistics networks allow for redistribution.</p><p id="__p9">We assumed that all persons were susceptible to the pandemic virus and that the general population epidemic occurred as a single wave after introduction of a single infectious case. We ignored the contribution of new introductions after the start of the epidemic. Persons were removed from the susceptible state, after infection, through recovery or death (<a href="/pmc/articles/PMC2725890/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1A</span></a>). Births, deaths from other causes, immigration, and emigration during the period were assumed to be negligible.</p><p id="__p10">We assumed a range of infectious periods similar to those from other studies; we also assumed that the disease was infectious at about the same time a person became symptomatic; i.e., the latent period coincided with the incubation period (<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979812"><em>9</em></a>,<a href="#R10" rid="R10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979814"><em>10</em></a>). A range of basic reproductive numbers (R<sub>0</sub>), based on these infectious and latent periods, were then used to generate epidemics in the general population with varying rates of transmission. These R<sub>0</sub> then determined the course of the HCW epidemic.</p><p id="__p11">HCWs were assumed to be exposed to influenza from 3 sources and may be more likely to be exposed than the general population (<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979818"><em>11</em></a>). The first source was exposures from colleagues (HCW-to-HCW transmission) at a proportion (&#x003c9;); the second was from persons outside the workplace (<em>1-&#x003c9;</em>). In the absence of published estimates, the base case assumed that 50% of infections were attributed to HCW-to-HCW transmission, with sensitivity analysis performed from 20% to 80%. The third source was from general population case-patients (patient-to-HCW transmission), expressed as the ratio of susceptible HCWs who could be infected by incident case-patients who sought treatment from the healthcare system (H/P). The extent of transmission is dependent on interventions such as barrier precautions (<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979799"><em>11</em></a>). On the basis of findings from exploratory analysis, increasing the H/P ratio moves the HCW epidemic earlier; at an H/P of 2.08, the HCW epidemic peaks before the start of prophylaxis, negating the outcomes of prophylaxis. Therefore, H/P values &#x0003e;2 do not substantially contribute to the outcomes and study conclusions, and sensitivity analysis was performed for H/P from 0 to 2 (<a href="#SD2" rid="SD2" class=" local-data">Technical Appendix</a>). Transmission from HCWs to patients was assumed negligible compared with other sources of infection for the general population, and the general population epidemic was independent of transmission dynamics within the HCW population.</p><p id="__p12" class="p p-last">Once infected, an HCW would have 4 outcomes based on absenteeism (<a href="/pmc/articles/PMC2725890/figure/F1/" target="figure" class="fig-table-link figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span>Figure 1B</span></a>). Those with asymptomatic infection were assumed to be fit for work. Absenteeism due to symptomatic infection, hospitalization, and death was determined for the different strategies. The study assumed that all HCWs were absent from work while symptomatic and that prophylaxis reduced HCW-to-HCW transmission (<a href="#R9" rid="R9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979801"><em>9</em></a>). Each scenario was further analyzed on the basis of different R<sub>0;</sub> the disease&#x02019;s incubation and infectious periods were kept constant.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Pandemic Duration and Prophylaxis Initiation</h3><p id="__p13" class="p p-first-last">The point of local detection of pandemic influenza depends on various factors and is unknown. Approximately 2,800 cases of influenzalike illness (ILI) occur per day in Singapore (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154070"><em>2</em></a>), of which a small fraction is sampled for virologic surveillance (<a href="#R12" rid="R12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154076"><em>12</em></a>). The base case assumed that the pandemic influenza subtype would be detected when incident symptomatic cases exceeded 10% of baseline ILI rates. The pandemic duration was defined as the period when incident pandemic influenza cases remained above this stated level. Prophylaxis was given to HCWs at the time of disease detection and continued for the planned duration. We conducted sensitivity analysis for starting prophylaxis on introduction of the first case and when incident cases exceeded 1%&#x02013;100% of the baseline ILI rate.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Other Input Parameters</h3><p id="__p14" class="p p-first">The input parameters for analysis (<a href="/pmc/articles/PMC2725890/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>) were obtained from local sources when available as detailed in a previous study on stockpiling strategies in Singapore (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154074"><em>2</em></a>). Other values were obtained from international sources. To account for uncertainties, wide ranges were used for analysis.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T1"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Parameters of neuraminadase inhibitor stockpiling strategies model*</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657675534288" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Parameter<hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Notation&#x02020;<hr /></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Minimum&#x02021;<hr /></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Base case&#x02021;<hr /></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Maximum&#x02021;<hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Reference<hr /></th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><em>Input</em><hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><hr /></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><hr /></th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">General population</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1"><em>N<sub>g</sub></em></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">4,350,000</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R13" rid="R13" class=" bibr popnode"><em>13</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Healthcare staff</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1"><em>N<sub>h</sub></em></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">20,000</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Estimated</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">ILI rate, per day</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b9;</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2,800</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><em>Transmission dynamics</em></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Incubation and latent period, d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b1;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1.0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2.0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">3.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>,<a href="#R10" rid="R10" class=" bibr popnode"><em>10</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Infectious period, d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b3;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1.5</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">4.1</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">7.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>,<a href="#R10" rid="R10" class=" bibr popnode"><em>10</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Reproductive number</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">R<sub>0</sub></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1.5</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2.5</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">6.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>,<a href="#R14" rid="R14" class=" bibr popnode"><em>14</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Transmission probability/d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b2;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.37</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.61</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Calculated, R/&#x003b3;</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">HCW-to-HCW transmission</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003c9;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.2</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.5</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.8</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">See text</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">HCW infections caused by incident cases of clinical influenza (<em>H/P)</em></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b4;</th><th valign="bottom" colspan="2" align="center" scope="colgroup" rowspan="1">0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">See text</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Detection threshold, proportion of baseline ILI rate</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003bd;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Introduction of 1st case</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.1</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">See text</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"><em>Disease severity and antiviral efficacy</em></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"></th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Hospitalization rate (HCW)/100,000 infected&#x000a7;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b7;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">12.4</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">88.6</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">186.7</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Length of stay and medical leave if hospitalized, d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003c6;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">9.0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">12.0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">20.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">(2)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Case-fatality rate (HCW)/100,000 infected&#x000a7;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003bc;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1.9</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">20.3</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">65.1</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Proportion of infected persons without prophylaxis who have symptoms</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1"><em>&#x003b8;<sub>1</sub></em></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.50</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.67</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.80</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>,<a href="#R15" rid="R15" class=" bibr popnode"><em>15</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Oseltamivir efficacy for preventing infection in exposed persons</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b5;<sub>1</sub></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.28</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.35</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.52</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>,<a href="#R16" rid="R16" class=" bibr popnode"><em>16</em></a>,<a href="#R17" rid="R17" class=" bibr popnode"><em>17</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Oseltamivir efficacy for preventing disease in infected persons</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b5;<sub>2</sub></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.5</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.6</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.9</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>,<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Oseltamivir efficacy for preventing transmission of infection by infected persons</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003b5;<sub>3</sub></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.6</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.8</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.98</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R9" rid="R9" class=" bibr popnode"><em>9</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Proportion of infected persons receiving oseltamivir prophylaxis who have symptoms</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1"><em>&#x003b8;<sub>2</sub></em></th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.07</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">-</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.2</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Calculated, <em>&#x003b8;<sub>2</sub>&#x000a0;=&#x000a0;&#x003b8;<sub>1</sub>(1&#x02212;&#x003b5;<sub>2</sub>)</em></th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Medical leave without treatment, d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003c3;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">4</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">5</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>)</th></tr><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Reduction in medical leave with oseltamivir treatment, d</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">&#x003c7;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">0.1</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">1.0</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">2.0</th><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>)</th></tr></thead><tbody><tr><td valign="bottom" align="left" scope="row" rowspan="1" colspan="1">Reduction in hospitalization or case-fatality rate with treatment</td><td valign="bottom" align="center" rowspan="1" colspan="1">&#x003c8;</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.4</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.6</td><td valign="bottom" align="center" rowspan="1" colspan="1">0.8</td><td valign="bottom" align="left" rowspan="1" colspan="1"> (<a href="#R2" rid="R2" class=" bibr popnode"><em>2</em></a>,<a href="#R18" rid="R18" class=" bibr popnode"><em>18</em></a>)</td></tr></tbody></table></div><div id="largeobj_idm140657675534288" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/table/T1/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p15">*HCW, healthcare workers, ILI, influenzalike illness.</p><p id="__p16">&#x02020;Notations are used in the equations listed in the <a href="#SD1" rid="SD1" class=" local-data">Appendix</a>.</p><p id="__p17">&#x02021;Base case values are given with the minimum and maximum values used in the model where applicable.</p><p id="__p18">&#x000a7;Based on hospitalizations and deaths among those with clinical influenza.</p></div></div><p id="__p19" class="p p-last">HCWs were assumed to be adults 20&#x02013;64 years of age with a mix of persons at low and high risk for influenza complications similar to that in the general population. Hospitalization and case-fatality rates were estimated for a pandemic of average severity (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154073"><em>2</em></a>). To account for the effect of severe pandemics, a scenario using mortality rates from the 1918 &#x0201c;Spanish flu&#x0201d; (5% average) and correlated hospitalization rates was performed (<a href="#R19" rid="R19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979821"><em>19</em></a>).</p></div><div id="__sec5" class="sec sec-last"><h3 id="__sec5title">Outcome Variables and Sensitivity Analysis</h3><p id="__p20" class="p p-first">Outcome variables from the analyses included pandemic duration, peak staff absenteeism, and days with absenteeism &#x0003e;5%. For parameters relating to disease severity and antiviral efficacy, 1-way sensitivity analysis was performed to determine the effect on outcomes. In addition, Monte Carlo simulation analysis, with 1,000 iterations per scenario, was performed with the range of parameter estimates modeled as triangular distributions. For parameters pertaining to transmission dynamics, separate analyses were performed to determine the effects of variations in HCW-to-HCW and patient-to-HCW transmission. We also tested the outcome effects of assuming different latent and infectious periods. Epidemics with similar R<sub>0</sub> but different latent and infectious periods have different growth rates. To facilitate comparison between epidemics with different latent and infectious periods, both epidemic growth rates and R<sub>0</sub> values were presented. The relationship between latent and infectious period, R<sub>0,</sub> and growth rates was described by Mills et al. (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979811"><em>14</em></a>) and elaborated in the <a href="#SD2" rid="SD2" class=" local-data">Technical Appendix</a>. Finally, the outcomes were determined for the various strategies upon initiation of prophylaxis at different times.</p><p id="__p21" class="p p-last">We used Berkeley-Madonna 8.3 software (University of California, Berkeley, CA, USA) to run the model. Details of the equations are shown in the <a href="#SD1" rid="SD1" class=" local-data">Appendix</a>; additional methods and results are shown in the <a href="#SD2" rid="SD2" class=" local-data">Technical Appendix</a>.</p></div></div><div id="__sec6" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec6title">Results</h2><p id="__p22" class="p p-first">The epidemic curve for a base-case pandemic with R<sub>0</sub> of 2.5 had a 12-week duration (<a href="/pmc/articles/PMC2725890/figure/F2/" target="figure" class="fig-table-link figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span>Figure 2</span></a>). When no action was taken, peak HCW absenteeism was &#x02248;10%. Treatment only, using 121,000 doses of oseltamivir, decreased peak absenteeism to 8%. Prophylaxis for 4 weeks required 117,000 treatment doses in addition to 560,000 dedicated prophylaxis doses (equivalent to treatment courses for 1.6% of the general population) and led to higher peak absenteeism than treatment only. Eight weeks of prophylaxis required 52,000 treatment doses in addition to 1.12 million dedicated prophylaxis doses (equivalent to treatment courses for 2.7% of the general population) and reduced peak absenteeism to &#x02248;2%; the peak occurred as a secondary increase after termination of prophylaxis. Discontinuing prophylaxis for clinical infections and redistributing stockpiles to prolong prophylaxis in other HCWs did not provide additional outcome benefits because the doses saved were insignificant; &#x0003e;96% were used during the preplanned duration for the relevant scenarios. From the Monte Carlo simulation of peak absenteeism for different strategies in a pandemic with R<sub>0</sub> of 2.5, with varying disease severity and antiviral efficacy parameters, 6 weeks of prophylaxis was sufficient under all scenarios to have a net benefit over treatment only (<a href="/pmc/articles/PMC2725890/figure/F3/" target="figure" class="fig-table-link figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span>Figure 3</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a href="/pmc/articles/PMC2725890/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657680037280" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2725890_06-0309-F2.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-F2.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2725890/bin/06-0309-F2.jpg" /></a></div><div id="largeobj_idm140657680037280" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/figure/F2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="/pmc/articles/PMC2725890/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p23">Dynamics of population infections and the effect of different strategies on absenteeism among healthcare workers for a base-case pandemic.</p></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a href="/pmc/articles/PMC2725890/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657678142240" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2725890_06-0309-F3.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-F3.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2725890/bin/06-0309-F3.jpg" /></a></div><div id="largeobj_idm140657678142240" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/figure/F3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="/pmc/articles/PMC2725890/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p24">Simulation analysis of the difference in mean peak absenteeism for different strategies in an R<sub>0</sub> = 2.5 (base-case) pandemic (50th percentile shown in solid bars with the 5th and 95th percentiles shown in error bars).</p></div></div></div><p id="__p25">One-way sensitivity analyses showed that the following input parameters had the most effect on peak absenteeism: &#x0201c;days of medical leave without treatment,&#x0201d; with 15%&#x02013;96% variation from the baseline outcome, depending on the R<sub>0</sub> and strategy used; &#x0201c;reduction in medical leave with treatment&#x0201d; with 22%&#x02013;61% variation; &#x0201c;symptomatic proportion in infected persons without prophylaxis&#x0201d; with 19%&#x02013;25% variation; and &#x0201c;oseltamivir efficacy in preventing disease in infected persons&#x0201d; with 21%&#x02013;87% variation. Other input parameters had less effect on the outcome.</p><p id="__p26"><a href="/pmc/articles/PMC2725890/table/T2/" target="table" class="fig-table-link figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span>Table 2</span></a> shows the outcomes for pandemics with different R<sub>0</sub>. If no action was taken for pandemics with R<sub>0</sub> &#x02265;2, absenteeism exceeded 5% for &#x0003e;15 days. In pandemics with lower R<sub>0</sub> (&#x02264;2), pandemic durations were longer and peak absenteeism did not exceed 10%. Treatment only in these pandemics reduced peak absenteeism by as much as 25% compared with no action. However, prophylaxis of &#x02264;8 weeks did not accrue substantial benefits over treatment only.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="T2"><h3>Table 2</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>Effects of influenza pandemic prevention strategies on healthcare worker absenteeism</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657678135408" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th rowspan="2" valign="bottom" colspan="2" align="left" scope="colgroup">Reproductive no. (R<sub>0</sub>)<hr /></th><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Pandemic duration, wk<hr /></th><th colspan="6" valign="top" align="center" scope="colgroup" rowspan="1">Peak % absent by strategy<br />(days with &#x0003e;5% absent)</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">No action<hr /></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Treatment only<hr /></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2 weeks&#x02019; prophylaxis<hr /></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">4 weeks&#x02019; prophylaxis<hr /></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">6 weeks&#x02019; prophylaxis<hr /></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">8 weeks&#x02019; prophylaxis<hr /></th></tr><tr><th valign="bottom" colspan="2" align="left" scope="colgroup" rowspan="1">1.5</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">24</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.8 (0)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.1 (0)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.1 (0)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.1 (0)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.2 (0)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">2.3 (0)</th></tr></thead><tbody><tr><td valign="bottom" colspan="2" align="left" scope="row" rowspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">15</td><td valign="top" align="center" rowspan="1" colspan="1">6.7 (17.8)</td><td valign="top" align="center" rowspan="1" colspan="1">5.1 (5.4)</td><td valign="top" align="center" rowspan="1" colspan="1">5.2 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">5.5 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">5.9 (11))</td><td valign="top" align="center" rowspan="1" colspan="1">4.6 (0)</td></tr><tr><td valign="bottom" colspan="2" align="left" scope="row" rowspan="1">2.5</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">10.2 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">7.9 (16)</td><td valign="top" align="center" rowspan="1" colspan="1">8.1 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">8.8 (16.2)</td><td valign="top" align="center" rowspan="1" colspan="1">7.2 (10.8)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (0)</td></tr><tr><td valign="bottom" colspan="2" align="left" scope="row" rowspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="center" rowspan="1" colspan="1">13 (20.6)</td><td valign="top" align="center" rowspan="1" colspan="1">10.2 (16.6)</td><td valign="top" align="center" rowspan="1" colspan="1">10.6 (16.7)</td><td valign="top" align="center" rowspan="1" colspan="1">11.4 (15)</td><td valign="top" align="center" rowspan="1" colspan="1">4.7 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">2.5 (0)</td></tr><tr><td valign="bottom" colspan="2" align="left" scope="row" rowspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">17.3 (18.7)</td><td valign="top" align="center" rowspan="1" colspan="1">13.9 (15.7)</td><td valign="top" align="center" rowspan="1" colspan="1">14.6 (15.4)</td><td valign="top" align="center" rowspan="1" colspan="1">10.8 (11.1)</td><td valign="top" align="center" rowspan="1" colspan="1">3.7 (0)</td><td valign="top" align="center" rowspan="1" colspan="1">3.7 (0)</td></tr><tr><td valign="bottom" colspan="2" align="left" scope="row" rowspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">22.5 (16.5)</td><td valign="top" align="center" rowspan="1" colspan="1">18.5 (13.9)</td><td valign="top" align="center" rowspan="1" colspan="1">19.7 (12.9)</td><td valign="top" align="center" rowspan="1" colspan="1">5.5 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">5.5 (4.1)</td><td valign="top" align="center" rowspan="1" colspan="1">5.5 (4.1)</td></tr><tr><td valign="bottom" align="left" scope="row" rowspan="1" colspan="1">Pandemic similar to 1918 &#x0201c;Spanish flu&#x0201d;*</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="bottom" align="center" rowspan="1" colspan="1">20.2 (28.6)</td><td valign="bottom" align="center" rowspan="1" colspan="1">15.1 (18.3)</td><td valign="bottom" align="center" rowspan="1" colspan="1">15.8 (17.9)</td><td valign="bottom" align="center" rowspan="1" colspan="1">11.6 (13)</td><td valign="bottom" align="center" rowspan="1" colspan="1">4.1 (0)</td><td valign="bottom" align="center" rowspan="1" colspan="1">4.1 (0)</td></tr></tbody></table></div><div id="largeobj_idm140657678135408" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/table/T2/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><p id="__p27">*R<sub>0</sub> =4; mortality rate = 5% (hospitalization set to the ratio of the hospitalization rates to the case-fatality rates in <a href="/pmc/articles/PMC2725890/table/T1/" target="table" class="fig-table-link figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span>Table 1</span></a>).</p></div></div><p id="__p28">Pandemics with higher R<sub>0</sub> (&#x02265;4) were of shorter durations; peak absenteeism was &#x0003e;20% in some scenarios. Treatment only reduced peak absenteeism by &#x0003e;15%, and 6 weeks of prophylaxis was sufficient to reduce peak absenteeism by &#x0003e;75% over no action. Across all R<sub>0</sub>, insufficient durations of prophylaxis increased peak absenteeism compared with results for treatment only.</p><p id="__p29">During a pandemic similar in severity to the 1918 influenza pandemic, with a 5% mortality rate and R<sub>0</sub> of 4 (<a href="#R14" rid="R14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979810"><em>14</em></a>), peak absenteeism reached 20% with no action; hospitalizations and deaths contributed substantially to absenteeism, unlike the situation in less severe pandemics. The 3 strategies&#x02014;treatment only, 4 weeks of prophylaxis, and 6 weeks of prophylaxis&#x02014;reduced peak absenteeism by 25%, 43%, and 80%, respectively.</p><p id="__p30">We also tested the adequacy of prophylaxis for a base-case pandemic under different scenarios for HCW-to-HCW and patient-to-HCW transmission. Higher HCW-to-HCW transmission resulted in an increased postprophylaxis epidemic peak. The HCW epidemic coincided with the general population epidemic if the patient-to-HCW infections variable was minimized (H/P = 0). Increasing H/P alone shifted the HCW epidemic such that it preceded the general population epidemic and amplified peak absenteeism by as much as 1.4 for the base case. For the prophylaxis strategies, increasing the patient-to-HCW transmission resulted in the distribution of HCW absenteeism away from the postprophylaxis period into the pre- and intraprophylaxis periods, which resulted in lower peak absenteeism up to a point. For H/P &#x0003e;2.0, peak absenteeism occurred before initiation of prophylaxis, negating the effect of longer durations of prophylaxis. Under all HCW-to-HCW and patient-to-HCW transmission scenarios for a base-case pandemic, 6 weeks of prophylaxis provided equal or superior results to treatment only; 8 weeks of prophylaxis was always superior (<a href="#SD2" rid="SD2" class=" local-data">Technical Appendix</a>).</p><p id="__p31"><a href="/pmc/articles/PMC2725890/figure/F4/" target="figure" class="fig-table-link figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span>Figure 4</span></a> shows the changes in peak absenteeism when latent and infectious periods were varied. For any rate of growth, assuming different latent periods changed peak absenteeism by &#x0003c;1% for most scenarios; assuming longer infectious periods increased peak absenteeism by &#x0003c;3%. However, epidemics with higher growth rates for any latent and infectious periods increased peak absenteeism by &#x0003e;10% when no action was taken. Although changes in the transmission parameters substantially changed peak absenteeism levels for certain scenarios, the overall conclusions remained similar. For epidemics with low peak absenteeism (&#x0003c;10%) and prolonged duration (low growth rate), prophylaxis strategies were less effective than treatment only. In contrast, for epidemics with higher peak absenteeism (&#x0003e;10%) and shorter duration (high growth rate), prophylaxis of <span class="underline">&#x0003e;</span>6 weeks was superior to treatment only.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F4" co-legend-rid="lgnd_F4"><a href="/pmc/articles/PMC2725890/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657670484096" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2725890_06-0309-F4.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-F4.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2725890/bin/06-0309-F4.jpg" /></a></div><div id="largeobj_idm140657670484096" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/figure/F4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="/pmc/articles/PMC2725890/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="__p32">Peak absenteeism with different treatment and prophylaxis strategies varying rates of growth (&#x003b6;)*, latent periods (&#x003b1;), and infectious duration (&#x003b3;).&#x02020; *&#x003b6; is the initial rate of growth of the epidemic curve and is determined by the reproductive potential and the infectious agent&#x02019;s doubling time (&#x003a4;). The latter is related to the rate of growth by the following equation, <br /><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-M1.jpg" src="/pmc/articles/PMC2725890/bin/06-0309-M1.jpg" class="equation" />. <br />&#x02020;Tx refers to treatment; Rx refers to prophylaxis.</p></div></div></div><p id="__p33" class="p"><a href="/pmc/articles/PMC2725890/figure/F5/" target="figure" class="fig-table-link figpopup" rid-figpopup="F5" rid-ob="ob-F5" co-legend-rid="lgnd_F5"><span>Figure 5</span></a> shows the adequacy of prophylaxis for a base-case pandemic under different prophylaxis initiation points based on pandemic detection. Earlier detection and prophylaxis initiation resulted in a greater likelihood that shorter durations of prophylaxis would be ineffective. If prophylaxis were initiated on entry of the first pandemic case, 14 weeks of prophylaxis would be required for maximal benefit. Prophylaxis for 6 weeks was more effective than treatment only if it was initiated when incident pandemic cases in the general population exceeded 10% of the ILI rate, whereas 8 weeks of prophylaxis was effective when incident pandemic cases exceeded 1%.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="F5" co-legend-rid="lgnd_F5"><a href="/pmc/articles/PMC2725890/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140657677959024" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2725890_06-0309-F5.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 06-0309-F5.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2725890/bin/06-0309-F5.jpg" /></a></div><div id="largeobj_idm140657677959024" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2725890/figure/F5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_F5"><div><a class="figpopup" href="/pmc/articles/PMC2725890/figure/F5/" target="figure" rid-figpopup="F5" rid-ob="ob-F5">Figure 5</a></div><!--caption a7--><div class="caption"><p id="__p34">Peak absenteeism observed with different times of initiating prophylaxis, according to point of detection in a base-case pandemic.</p></div></div></div></div><div id="__sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec7title">Discussion</h2><p id="__p35" class="p p-first">During an influenza pandemic, essential services such as healthcare must be maintained, especially during the pandemic&#x02019;s peak, when the maximal number of patients require care, and healthcare services can ill afford absenteeism due to infection. Absenteeism may also occur for reasons such as background illnesses and the need to care for ill relatives. During the severe acute respiratory syndrome epidemic in Singapore in 2003, schools were closed for weeks. Although no study documented the resultant workplace absenteeism, parents may have taken time off to care for their children. The New Zealand government has predicted overall absenteeism levels as high as 40% (<a href="#R20" rid="R20" class=" bibr popnode"><em>20</em></a>), and actual pandemic workplace absenteeism levels will likely exceed those shown in this study.</p><p id="__p36">Treatment and timely use of prophylaxis with neuraminidase inhibitors reduce HCW absenteeism compared with no action. As shown in previous studies, treatment provides benefits over no action and should be considered in preparedness plans to reduce illness and death (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154078"><em>2</em></a>,<a href="#R3" rid="R3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154075"><em>3</em></a>,<a href="#R21" rid="R21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_272666615"><em>21</em></a>). Using prophylaxis to prevent infection results in a secondary increase in infections after prophylaxis is stopped because susceptible HCWs remain in the general population when transmission occurs. Insufficient durations of prophylaxis thus result in poorer outcomes than treatment only. For prophylaxis strategies to accrue more benefits than treatment only, the prophylaxis duration must be sufficient to cover the pandemic&#x02019;s peak. Eight weeks of prophylaxis, the maximum safe duration previously studied (<a href="#R22" rid="R22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979805"><em>22</em></a>), was sufficient to provide a substantial reduction in peak absenteeism under a broad range of assumptions for more severe pandemics where peak absenteeism exceeded 10%. Six weeks of prophylaxis was marginally beneficial, if one assumes that prophylaxis was initiated after incident pandemic cases exceeded 10% of the baseline ILI rate.</p><p id="__p37">An important policy consideration is the timing of prophylaxis initiation. Improved surveillance, critical for early detection, paradoxically increases the likelihood of initiating prophylaxis too early, causing predetermined estimates of stockpile duration to be inaccurate. Many countries have developed comprehensive preparedness plans to reduce a pandemic&#x02019;s spread. These may prolong the pandemic&#x02019;s duration within the country, which would compound the issue of stockpile adequacy. If prophylaxis is started prematurely, stockpiles will be exhausted before the delayed waves of the pandemic occur and thus will not reduce absenteeism more than would treatment only. Prophylaxis should not be initiated until a certain point in the epidemic curve, but this may be difficult, given public sentiment and pressure. Further studies are needed to determine the ideal time for prophylaxis initiation and the role of surveillance in evaluating the pandemic phases and projected spread.</p><p id="__p38">The current avian influenza outbreaks have increased fear of an imminent severe pandemic. Pandemics of lesser severity place fewer requirements on essential services. Our study showed that such pandemics also result in lower staff absenteeism rates; treatment and prophylaxis may thus be less critical to service continuity. On the contrary, severe pandemics increase the strain because of the numbers of patients, hospitalizations, and deaths and the reduced response capacity of healthcare services. For pandemics with high mortality rates, high growth rates, or high R<sub>0</sub>, prophylaxis provides greater benefits than it does for pandemics with lower mortality rates, low growth rates, or low R<sub>0</sub>; and the required duration of prophylaxis is shorter.</p><p id="__p39" class="p p-last">Our results are subject to several limitations. The true level of transmission in HCWs remains unknown. In a heightened state of alertness, HCWs will be equipped with personal protective equipment, and patient-HCW transmission may be minimized, resulting in lower absenteeism rates (<a href="#R11" rid="R11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_176979819"><em>11</em></a>). Another limitation is that effects over the entire HCW population were aggregated. In reality, subsets of HCWs exist with varying levels of exposure. Stochastic variation and nosocomial outbreaks, which were not modeled, may result in higher local absenteeism rates than predicted by this model. Further studies that use individual-based stochastic models may provide improved representation of disease transmission to test other interventions. Studies should also consider modeling the effect of multiple pandemic waves. Finally, the study parameters used were based on historical data; the validity of the projections will depend on how the next pandemic compares with its precedents.</p></div><div id="__sec8" class="tsec sec"><h2 class="head no_bottom_margin" id="__sec8title">Conclusion</h2><p id="__p40" class="p p-first-last">Countries must consider the effects of an influenza pandemic on essential services. Those planning neuraminidase inhibitor stockpiling for treatment and prophylaxis of essential staff should consider the relatively small quantities required. Treatment and 8 weeks of prophylaxis for HCWs in Singapore costs US $2 million, compared with US $400 million for a similar populationwide stockpile and the &#x02248;US $20 million spent for national stockpiling (<a href="#R2" rid="R2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_261154077"><em>2</em></a>). In severe pandemics, when the need for protection is greatest, prophylaxis of short duration has a potential role in mitigating the effects. For prophylaxis strategies to succeed, stockpiles must be adequate and their deployment must be timed to cover the pandemic&#x02019;s peak. If adequacy and timeliness cannot be achieved, prophylaxis may result in higher absenteeism than treatment only, which makes the latter strategy a more effective option.</p></div><div id="__sec9" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="__sec9title">Supplementary Material</h2><!--/article/body/sec/--><div class="sec suppmat" id="SD1"><!--caption a9--><strong>Appendix: </strong><p id="__p41">Modified SEIR Model</p><div class="sup-box half_rhythm" id="d32e1075"><a href="/pmc/articles/PMC2725890/bin/06-0309_app-s1.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(65K, pdf)</sup></div></div><div class="sec suppmat" id="SD2"><!--caption a9--><strong>Technical Appendix: </strong><p id="__p42">Supplementary material including additional methodology, results, and discussion.</p><div class="sup-box half_rhythm" id="d32e1082"><a href="/pmc/articles/PMC2725890/bin/06-0309_Techapp-s2.pdf" data-ga-action="click_feat_suppl">Click here to view.</a><sup>(283K, pdf)</sup></div></div></div><div id="idm140657673324352" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140657673324352title">Acknowledgments</h2><div class="sec"><p id="__p44">We acknowledge Gina Fernandez for her kind assistance and colleagues at the Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, for their support.</p></div></div><div id="idm140657673323296" class="tsec sec headless whole_rhythm"><h2 class="head no_bottom_margin" id="idm140657673323296title">Biographies</h2><div class="bio"><div class="left">&#x02022;\xc2\xa0</div><p id="__p45" class="p p-first-last">Dr Lee is a preventive medicine physician with the Singapore Ministry of Defence and the Communicable Disease Centre, Tan Tock Seng Hospital, Singapore. His research interests include emerging infectious diseases preparedness, health economics, and health services research.</p></div><div class="bio"><div class="left">&#x02022;\xc2\xa0</div><p id="__p46" class="p p-first-last">Dr Chen is a preventive medicine physician at the Communicable Disease Centre, Tan Tock Seng Hospital, Singapore. He is pursuing a PhD in infectious disease epidemiology. His interests include emerging infectious diseases, HIV and other sexually transmitted infections, and the application of mathematical modeling to infectious diseases.</p></div> </div><div id="idm140657673327152" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140657673327152title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140657673327024"><p id="__p43" class="p p-first-last"><em>Suggested citation for this article</em>: Lee VJ, Chen MI. Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza. Emerg Infect Dis. [serial on the Internet]. 2007 Mar [<em>date cited</em>]. Available from <a href="http://www.cdc.gov/eid/content/13/3/449.htm" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.cdc.gov/eid/content/13/3/449.htm</a></p></p></div></div><div id="idm140657675449312" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140657675449312title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="R1">1.  <span class="mixed-citation">World Health Organization Avian influenza and human pandemic influenza: summary report. Meeting held in Geneva, Switzerland, 7&#x02013;9 Nov 2005.  [cited 2006 Jan 15]. Available from <a href="http://www.who.int/mediacentre/events/2005/avian_influenza/summary_report_Nov_2005_meeting.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.who.int/mediacentre/events/2005/avian_influenza/summary_report_Nov_2005_meeting.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="R2">2.  <span class="mixed-citation">Lee VJ, Phua KH, Chen MI, Chow A, Ma S, Goh KT, et al.<span class="ref-title">Economics of neuraminidase inhibitor stockpiling for pandemic influenza, Singapore. </span><span class="ref-journal">Emerg Infect Dis</span> 2006;<span class="ref-vol">12</span>:95&#x02013;102 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3291387/">PMC free article</a>]</span> [<a href="/pubmed/16494724" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Economics+of+neuraminidase+inhibitor+stockpiling+for+pandemic+influenza,+Singapore.&amp;volume=12&amp;publication_year=2006&amp;pages=95-102&amp;pmid=16494724&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R3">3.  <span class="mixed-citation">Balicer RD, Huerta M, Davidovitch N, Grotto I <span class="ref-title">Cost-benefit of stockpiling drugs for influenza pandemic. </span><span class="ref-journal">Emerg Infect Dis</span> 2005;<span class="ref-vol">11</span>:1280. <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3320484/">PMC free article</a>]</span> [<a href="/pubmed/16102319" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Cost-benefit+of+stockpiling+drugs+for+influenza+pandemic.&amp;volume=11&amp;publication_year=2005&amp;pages=1280&amp;pmid=16102319&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R4">4.  <span class="mixed-citation">Cinti S, Chenoweth C, Monto AS <span class="ref-title">Preparing for pandemic influenza: should hospitals stockpile oseltamivir? </span><span class="ref-journal">Infect Control Hosp Epidemiol</span> 2005;<span class="ref-vol">26</span>:852&#x02013;4 10.1086/502507 [<a href="/pubmed/16320980" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F502507" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Infect+Control+Hosp+Epidemiol&amp;title=Preparing+for+pandemic+influenza:+should+hospitals+stockpile+oseltamivir?&amp;volume=26&amp;publication_year=2005&amp;pages=852-4&amp;pmid=16320980&amp;doi=10.1086/502507&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R5">5.  <span class="mixed-citation">Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al.<span class="ref-title">Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. </span><span class="ref-journal">Lancet</span> 2000;<span class="ref-vol">355</span>:1845&#x02013;50 10.1016/S0140-6736(00)02288-1 [<a href="/pubmed/10866439" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(00)02288-1" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Efficacy+and+safety+of+oseltamivir+in+treatment+of+acute+influenza:+a+randomized+controlled+trial.&amp;volume=355&amp;publication_year=2000&amp;pages=1845-50&amp;pmid=10866439&amp;doi=10.1016/S0140-6736(00)02288-1&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R6">6.  <span class="mixed-citation">Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F <span class="ref-title">Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. </span><span class="ref-journal">Arch Intern Med</span> 2003;<span class="ref-vol">163</span>:1667&#x02013;72 10.1001/archinte.163.14.1667 [<a href="/pubmed/12885681" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1001%2Farchinte.163.14.1667" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Intern+Med&amp;title=Impact+of+oseltamivir+treatment+on+influenza-related+lower+respiratory+tract+complications+and+hospitalizations.&amp;volume=163&amp;publication_year=2003&amp;pages=1667-72&amp;pmid=12885681&amp;doi=10.1001/archinte.163.14.1667&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R7">7.  <span class="mixed-citation">Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG <span class="ref-title">Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. </span><span class="ref-journal">BMJ</span> 2003;<span class="ref-vol">326</span>:1235 10.1136/bmj.326.7401.1235 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC161558/">PMC free article</a>]</span> [<a href="/pubmed/12791735" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1136%2Fbmj.326.7401.1235" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Effectiveness+of+neuraminidase+inhibitors+in+treatment+and+prevention+of+influenza+A+and+B:+systematic+review+and+meta-analyses+of+randomised+controlled+trials.&amp;volume=326&amp;publication_year=2003&amp;pages=1235&amp;pmid=12791735&amp;doi=10.1136/bmj.326.7401.1235&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R8">8.  <span class="mixed-citation">Moscona A <span class="ref-title">Neuraminidase inhibitors for influenza. </span><span class="ref-journal">N Engl J Med</span> 2005;<span class="ref-vol">353</span>:1363&#x02013;73 10.1056/NEJMra050740 [<a href="/pubmed/16192481" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMra050740" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Neuraminidase+inhibitors+for+influenza.&amp;volume=353&amp;publication_year=2005&amp;pages=1363-73&amp;pmid=16192481&amp;doi=10.1056/NEJMra050740&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R9">9.  <span class="mixed-citation">Longini IM Jr, Halloran ME, Nizam A, Yang Y <span class="ref-title">Containing pandemic influenza with antiviral agents. </span><span class="ref-journal">Am J Epidemiol</span> 2004;<span class="ref-vol">159</span>:623&#x02013;33 10.1093/aje/kwh092 [<a href="/pubmed/15033640" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Faje%2Fkwh092" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Epidemiol&amp;title=Containing+pandemic+influenza+with+antiviral+agents.&amp;volume=159&amp;publication_year=2004&amp;pages=623-33&amp;pmid=15033640&amp;doi=10.1093/aje/kwh092&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R10">10.  <span class="mixed-citation">Salgado CD, Farr BM, Hall KK, Hayden FG <span class="ref-title">Influenza in the acute hospital setting. </span><span class="ref-journal">Lancet Infect Dis</span> 2002;<span class="ref-vol">2</span>:145&#x02013;55 10.1016/S1473-3099(02)00221-9 [<a href="/pubmed/11944184" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1473-3099(02)00221-9" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet+Infect+Dis&amp;title=Influenza+in+the+acute+hospital+setting.&amp;volume=2&amp;publication_year=2002&amp;pages=145-55&amp;pmid=11944184&amp;doi=10.1016/S1473-3099(02)00221-9&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R11">11.  <span class="mixed-citation">Cox NJ, Subbarao K <span class="ref-title">Influenza. </span><span class="ref-journal">Lancet</span> 1999;<span class="ref-vol">354</span>:1277&#x02013;82 10.1016/S0140-6736(99)01241-6 [<a href="/pubmed/10520648" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0140-6736(99)01241-6" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Influenza.&amp;volume=354&amp;publication_year=1999&amp;pages=1277-82&amp;pmid=10520648&amp;doi=10.1016/S0140-6736(99)01241-6&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R12">12.  <span class="mixed-citation">Chow A, Ma S, Ling AE, Chew SK <span class="ref-title">Influenza-associated deaths in tropical Singapore. </span><span class="ref-journal">Emerg Infect Dis</span> 2006;<span class="ref-vol">12</span>:114&#x02013;21 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3293465/">PMC free article</a>]</span> [<a href="/pubmed/16494727" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Influenza-associated+deaths+in+tropical+Singapore.&amp;volume=12&amp;publication_year=2006&amp;pages=114-21&amp;pmid=16494727&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R13">13.  <span class="mixed-citation">Singapore Department of Statistics Key statistics. [cited 2005 Dec 21]. Available from <a href="http://www.singstat.gov.sg/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.singstat.gov.sg/</a></span></div><div class="ref-cit-blk half_rhythm" id="R14">14.  <span class="mixed-citation">Mills CE, Robins JM, Lipsitch M <span class="ref-title">Transmissibility of 1918 pandemic influenza. </span><span class="ref-journal">Nature</span> 2004;<span class="ref-vol">432</span>:904&#x02013;6 10.1038/nature03063 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7095078/">PMC free article</a>]</span> [<a href="/pubmed/15602562" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnature03063" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Transmissibility+of+1918+pandemic+influenza.&amp;volume=432&amp;publication_year=2004&amp;pages=904-6&amp;pmid=15602562&amp;doi=10.1038/nature03063&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R15">15.  <span class="mixed-citation">Fraser C, Riley S, Anderson RM, Ferguson NM <span class="ref-title">Factors that make an infectious disease outbreak controllable. </span><span class="ref-journal">Proc Natl Acad Sci U S A</span> 2004;<span class="ref-vol">101</span>:6146&#x02013;51 10.1073/pnas.0307506101 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC395937/">PMC free article</a>]</span> [<a href="/pubmed/15071187" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0307506101" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Factors+that+make+an+infectious+disease+outbreak+controllable.&amp;volume=101&amp;publication_year=2004&amp;pages=6146-51&amp;pmid=15071187&amp;doi=10.1073/pnas.0307506101&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R16">16.  <span class="mixed-citation">Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al.<span class="ref-title">Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. </span><span class="ref-journal">JAMA</span> 1999;<span class="ref-vol">282</span>:1240&#x02013;6 10.1001/jama.282.13.1240 [<a href="/pubmed/10517426" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1001%2Fjama.282.13.1240" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Use+of+the+oral+neuraminidase+inhibitor+oseltamivir+in+experimental+human+influenza:+randomized+controlled+trials+for+prevention+and+treatment.&amp;volume=282&amp;publication_year=1999&amp;pages=1240-6&amp;pmid=10517426&amp;doi=10.1001/jama.282.13.1240&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R17">17.  <span class="mixed-citation">Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al.<span class="ref-title">Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. </span><span class="ref-journal">JAMA</span> 2001;<span class="ref-vol">285</span>:748&#x02013;54 10.1001/jama.285.6.748 [<a href="/pubmed/11176912" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1001%2Fjama.285.6.748" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Oseltamivir+Post+Exposure+Prophylaxis+Investigator+Group.+Effectiveness+of+oseltamivir+in+preventing+influenza+in+household+contacts:+a+randomized+controlled+trial.&amp;volume=285&amp;publication_year=2001&amp;pages=748-54&amp;pmid=11176912&amp;doi=10.1001/jama.285.6.748&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R18">18.  <span class="mixed-citation">Moscona A <span class="ref-title">Neuraminidase inhibitors for influenza. </span><span class="ref-journal">N Engl J Med</span> 2005;<span class="ref-vol">353</span>:1363&#x02013;73 10.1056/NEJMra050740 [<a href="/pubmed/16192481" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1056%2FNEJMra050740" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Neuraminidase+inhibitors+for+influenza.&amp;volume=353&amp;publication_year=2005&amp;pages=1363-73&amp;pmid=16192481&amp;doi=10.1056/NEJMra050740&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R19">19.  <span class="mixed-citation">Glezen WP <span class="ref-title">Emerging infections: pandemic influenza. </span><span class="ref-journal">Epidemiol Rev</span> 1996;<span class="ref-vol">18</span>:64&#x02013;76 [<a href="/pubmed/8877331" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epidemiol+Rev&amp;title=Emerging+infections:+pandemic+influenza.&amp;volume=18&amp;publication_year=1996&amp;pages=64-76&amp;pmid=8877331&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R20">20.  <span class="mixed-citation">Influenza pandemic planning. Business continuity planning guide. New Zealand Ministry of Economic Development. [cited 2006 Jul 1]. Available from <a href="http://www.med.govt.nz/upload/27552/planning-guide.pdf" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.med.govt.nz/upload/27552/planning-guide.pdf</a></span></div><div class="ref-cit-blk half_rhythm" id="R21">21.  <span class="mixed-citation">Gani R <span class="ref-title">Potential impact of antiviral drug use during influenza pandemic. </span><span class="ref-journal">Emerg Infect Dis</span> 2005;<span class="ref-vol">11</span>:1355&#x02013;62 <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC3371825/">PMC free article</a>]</span> [<a href="/pubmed/16229762" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Emerg+Infect+Dis&amp;title=Potential+impact+of+antiviral+drug+use+during+influenza+pandemic.&amp;volume=11&amp;publication_year=2005&amp;pages=1355-62&amp;pmid=16229762&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="R22">22.  <span class="mixed-citation">Chik KW, Li CK, Chan PKS, Shing MMK, Lee V, Tam JSL, et al.<span class="ref-title">Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. </span><span class="ref-journal">Hong Kong Med J</span> 2004;<span class="ref-vol">10</span>:103&#x02013;6 [<a href="/pubmed/15075430" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hong+Kong+Med+J&amp;title=Oseltamivir+prophylaxis+during+the+influenza+season+in+a+paediatric+cancer+centre:+prospective+observational+study.&amp;volume=10&amp;publication_year=2004&amp;pages=103-6&amp;pmid=15075430&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2725890&amp;issue-id=180925&amp;journal-id=782&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">Emerging Infectious Diseases</span> are provided here courtesy of <strong>Centers for Disease Control and Prevention</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2725890/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2725890/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2725890/pdf/06-0309.pdf">PDF (284K)</a></li> | <li><a href="#" data-citationid="PMC2725890" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2725890%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2725890%2F&amp;text=Effectiveness%20of%20Neuraminidase%20Inhibitors%20for%20Preventing%20Staff%20Absenteeism%20during%20Pandemic%20Influenza%20"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2725890%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="17552099" data-aiid="2725890" data-aid="2725890" data-iid="180925" data-domainid="782" data-domain="eid" data-accid="PMC2725890" data-md5="f527bdcdfad427b2b671308d503c506d"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:21:12-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1BC4A7E9A3BD110000000004460446&amp;ncbi_session=8A1BC4A7E9A47F71_1094SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2725890%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=eid&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2725890/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1BC4A7E9A47F71_1094SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'